Capital Fund Management S.A. Sells 26,181 Shares of STAAR Surgical (NASDAQ:STAA)

Capital Fund Management S.A. lessened its holdings in STAAR Surgical (NASDAQ:STAA - Free Report) by 41.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 37,605 shares of the medical instruments supplier's stock after selling 26,181 shares during the quarter. Capital Fund Management S.A. owned 0.08% of STAAR Surgical worth $913,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in STAA. KLP Kapitalforvaltning AS purchased a new position in shares of STAAR Surgical in the fourth quarter worth about $180,000. FMR LLC grew its position in STAAR Surgical by 79.3% during the 3rd quarter. FMR LLC now owns 7,092 shares of the medical instruments supplier's stock worth $263,000 after acquiring an additional 3,136 shares during the last quarter. Quantbot Technologies LP purchased a new position in STAAR Surgical in the 4th quarter worth approximately $278,000. Y Intercept Hong Kong Ltd bought a new stake in STAAR Surgical in the fourth quarter valued at approximately $292,000. Finally, Counterpoint Mutual Funds LLC purchased a new stake in shares of STAAR Surgical during the fourth quarter valued at approximately $298,000. 96.70% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. acquired 36,532 shares of the company's stock in a transaction that occurred on Friday, February 14th. The shares were acquired at an average price of $15.49 per share, with a total value of $565,880.68. Following the completion of the purchase, the insider now directly owns 11,289,437 shares of the company's stock, valued at approximately $174,873,379.13. The trade was a 0.32 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders bought 1,742,581 shares of company stock worth $28,407,543. 1.00% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages recently commented on STAA. Wells Fargo & Company began coverage on shares of STAAR Surgical in a research note on Monday. They issued an "equal weight" rating and a $17.00 target price on the stock. Stifel Nicolaus lowered their price objective on shares of STAAR Surgical from $38.00 to $20.00 and set a "buy" rating for the company in a research note on Wednesday, February 12th. StockNews.com cut STAAR Surgical from a "hold" rating to a "sell" rating in a research note on Thursday, February 13th. Stephens restated an "equal weight" rating and set a $17.00 price target on shares of STAAR Surgical in a report on Tuesday, March 18th. Finally, Canaccord Genuity Group dropped their price objective on STAAR Surgical from $28.00 to $17.00 and set a "hold" rating for the company in a report on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, STAAR Surgical presently has an average rating of "Hold" and a consensus price target of $24.25.

STAAR Surgical Stock Up 3.9 %

Shares of NASDAQ:STAA traded up $0.64 during trading on Tuesday, hitting $17.17. The stock had a trading volume of 675,623 shares, compared to its average volume of 795,111. STAAR Surgical has a 12 month low of $13.50 and a 12 month high of $49.86. The company has a market capitalization of $846.91 million, a PE ratio of -41.88 and a beta of 0.75. The firm's fifty day moving average is $17.10 and its 200 day moving average is $23.09.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.